Abbott Labs (
) is scheduled to release its Q1 2014 earnings on Wednesday,
April 16. In the previous quarter, operational sales increased 3.3%
year-over-year (y-o-y) to $5.7 billion, driven by robust sales of
its Diagnostics, Vascular and Medical Optics products.
Nutritionals, the company's largest business segment,
continued to be impacted by the supplier recall that was initiated
in international markets in August of last year and reported a
marginal 1.1% y-o-y increase in operational sales. On the cost
side, the healthcare conglomerate improved its gross margins by 60
basis points to 55.4% on the back of improving operating margins in
the Nutritionals and Diagnostics businesses.
In the company's first quarter earnings, we expect operational
sales to grow in the mid-single digits, driven by continued growth
in Diagnostics and a marginal improvement in Nutritionals. Abbott's
management stated in the previous earnings call that the company
expected adjusted gross margins to decline to about 54% in the
first quarter of 2014 on account of increasing competition, foreign
exchange impacts and the supplier recall in Nutritionals. We
expect gross margins to match company estimates.
Emerging markets contributed about 40% of total sales in the
fourth quarter last year. We expect this to increase going forward
as Abbott increases its presence in emerging markets such as China,
India and Brazil, anticipating higher growth
prospects compared to developed regions. The company
introduced several new products last year and they are likely to
contribute significantly to sales in the near future.
We have a
price estimate of $40 for Abbott Labs
, implying a premium of over 5% to the current market price.
See our full analysis for Abbott Labs
Emerging Markets To Drive Growth In Sales
Sales in emerging markets grew 9% y-o-y in the previous quarter
driven by strong performance in the Adult Nutrition business,
Diagnostics and Established Pharmaceuticals (generic drugs).
Together, the Nutritionals, Diagnostics and Established
Pharmaceuticals divisions account for over 75% of Abbott's revenue
and are likely to derive most of their future growth from emerging
Countries such as China, India, Russia and Brazil continue to
grow at a faster rate than most developed economies, and have a
rapidly growing middle class population. McKinsey & Company
predicts that the urban household income in China will double by
2022 and that the majority of its urban consumers will earn between
$9,000 and $34,000 annually by that time. As the middle class
continues to grow in these markets, people are likely to increase
their discretionary spending on nutritional products (such as food
supplements) and point-of-care diagnostics.
New Products Could Boost Sales
In 2013, Abbott launched several new products across its
diversified businesses to boost sales and tap into new markets.
This included over 70 new products in the Nutritionals, Diagnostics
and Vascular divisions. Going forward, these new products are
expected to significantly contribute to the company's sales. Some
of these new products are as follows:
- XIENCE Xpedition drug-eluting stent - This is part of the
Endovascular division and currently sold in international markets
such as Japan and China. It is expected to contribute
significantly to Abbott's efforts in increasing its global share
in the stent market, along with its ABSORB product.
- MitraClip- This device is used to treat mitral (a valve in
the heart) regurgitation. Its markets include the U.S. and
Europe. It generated sales of about $130 million in 2013 and is
expected to grow to $200 million by the end of this year.
- SUPERA Veritas- It is a stent used for
treating blockages in blood vessels due to peripheral artery
disease (PAD), a sickness that ails 27 million people in Europe
and North America. It is also under FDA review for superficial
femoral artery (SFA) treatment in the U.S. This is the flagship
product of IDEV Technologies, a company which Abbott acquired in
- Catalys- This optics product allows surgeons
to replace manual steps in cataract surgery with computer-guided
laser technology. Abbott acquired this product as part of its
acquisition of OptiMedica Corporation in 2013 and it
provides Abbott an entry point in the large and fast-growing
laser cataract surgery market.
- Similac's Triple [ph] Pack- The company launched its flagship
Similac infant formula product with an enhanced packaging
solution for the online market in China. This is an example of
innovation within existing products to tap into new markets and
boost sales. ((
Abbott Reports Fourth-Quarter 2013 Results
, Abbott Labs, January 22, 2014))
See More at Trefis
View Interactive Institutional Research
(Powered by Trefis)